Table of Contents
Global Cancer Biopsy Market Size, Share, and COVID-19 Impact Analysis, By Product (Instruments, Kits And Consumables, Services), By Type (Tissue Biopsies, Liquid Biopsies, Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.
Related Topics
Hydrogen Storage Materials MarketCancer Biopsy Market Summary
The Global Cancer Biopsy Market Size Was Estimated at USD 30.12 Billion in 2024 and is Projected to Reach USD 73.89 Billion by 2035, Growing at a CAGR of 8.5% from 2025 to 2035. Rising cancer prevalence, increased demand for early and precise diagnosis, developments in liquid biopsy and molecular testing technologies, growing awareness of customised therapy, and an expanding global healthcare infrastructure are all factors propelling the growth of the cancer biopsy market.
Key Regional and Segment-Wise Insights
Global Market Forecast and Revenue Outlook
The market for cancer biopsy operates as a specialised healthcare segment which uses tissue and fluid samples to perform cancer diagnosis, assessment, and treatment monitoring. The medical procedure of biopsy stands as an essential diagnostic method which helps doctors identify cancer types and determine appropriate treatment plans. It also tracks disease progression. The market expands because cancer rates continue to rise worldwide, while healthcare providers need more straightforward diagnostic methods, and consumers become more aware of cancer detection during its early stages. The market will experience growth because of the rising demand for personalised treatment, which needs precise biopsy outcomes, and because of increasing elderly populations, advancing cancer research and expanding healthcare budgets.
Technological progress has led to a complete transformation of cancer biopsy procedures. Next-generation sequencing (NGS), digital pathology, and liquid biopsy represent three technological breakthroughs which speed up cancer detection. They enhance its safety and precision. These technologies lessen the need for intrusive treatments and enable real-time monitoring. Public awareness campaigns, combined with financial backing and supportive legal frameworks, enable governments worldwide to promote early cancer detection. The U.S. Cancer Moonshot and national cancer control programs speed up research and improve diagnostic access while fostering public-private partnerships to achieve better patient results.
Product Insights
The kits and consumables segment led the cancer biopsy market with the largest revenue share of 61.5% in 2024. The main reason for this dominance stems from the regular and ongoing needs to use consumables during biopsy procedures when performing tests with reagents, assay kits, and collecting devices. The continuous requirement for these products throughout all diagnostic stages, which involve sample preparation and analysis. Detection maintains a steady market demand. The segment growth stems from three key factors, which include the expanding application of liquid biopsy technologies, automated biopsy testing, and better molecular diagnostic kits. The global cancer biopsy market shows dominance from this category because major industry players dedicate increasing funds to create affordable biopsy consumables with enhanced sensitivity.
The instruments segment of the cancer biopsy market is expected to grow at the fastest CAGR during the projection period. The rapid market expansion results from ongoing technical progress in imaging and biopsy guidance systems and automated tissue sampling tools, which boost both precision and operational efficiency. The market growth results from expanding diagnostic technology adoption, which includes robotic biopsy systems and digital pathology scanners, and next-generation sequencing (NGS) platforms. The rising cancer rates, together with the critical need for precise early diagnosis, make healthcare facilities invest in advanced biopsy technology. The equipment segment's faster expansion in the cancer biopsy market is further supported by growing research efforts. It integrates AI and machine learning for better diagnostic interpretation.
Type Insights
The tissue biopsies segment led the cancer biopsy market during 2024 with the largest revenue share of 60.8%. The extensive use of tissue biopsy as the gold standard for cancer diagnosis and histological evaluation is responsible for this dominance. Doctors use tissue biopsies as essential tools to identify cancer with precision because they reveal complete information about tumour characteristics, cellular makeup, and molecular details. The market segments experience growth because solid tumours, including colorectal cancer, lung cancer, and breast cancer, become more common. The accuracy of medical diagnoses has improved because of better molecular pathology techniques, imaging-based sample collection methods, and advanced biopsy needle technology. The worldwide cancer biopsy market maintains its leading position because medical professionals increasingly accept tissue-based genetic profiling for clinical applications.
The liquid biopsy segment of the cancer biopsy market is expected to grow at the fastest CAGR throughout the forecast period. The main driver for this growth comes from the increasing requirement for fast, non-invasive diagnostic tools which deliver precise results during early cancer detection and monitoring. Real-time disease tracking and low patient discomfort are two major benefits of liquid biopsies, which examine circulating tumour DNA (ctDNA), exosomes, and circulating tumour cells (CTCs) from blood samples. The development of therapy selection and customised medicine through liquid biopsy technology has accelerated its market acceptance. The global cancer biopsy market experiences rapid expansion because of ongoing advancements in next-generation sequencing (NGS), biomarker detection, and rising financial support for cancer research and diagnostic development.
Regional Insights
North America leads the global cancer biopsy market with the largest revenue share of 40.3% in 2024. The region maintains its leadership position because it has adopted modern diagnostic technology at a high rate while dealing with elevated cancer rates and possessing advanced healthcare systems. The market continues to grow because major industry players conduct extensive research and development activities while introducing new biopsy equipment and molecular diagnostic tools at early stages. The region maintains its dominance because of favourable reimbursement policies and increased public understanding of cancer screening, and expanding government funding for precision oncology research. The expanding use of next-generation sequencing (NGS) and liquid biopsy technologies enables North America to lead the global cancer biopsy market.
Europe Cancer Biopsy Market Trends
The European cancer biopsy market held a substantial revenue share in 2024 because new diagnostic technologies spread throughout the region and consumers became more aware of early detection, while cancer cases increased. The German healthcare system and oncology research funding allow Germany, the United Kingdom, and France to lead in oncology research. The market continues to grow because patients want biopsy procedures that require less invasive methods through liquid biopsy tests. The development of diagnostic capabilities continues through supportive government programs and advantageous reimbursement schemes, and local research institutions. These institutions actively contribute to precision medicine and cancer genomics. Public health organisations in Europe join forces with biotechnology companies to create breakthroughs. This establishes the region as a dominant player in the worldwide cancer biopsy market.
Asia Pacific Cancer Biopsy Market Trends
The Asia Pacific cancer biopsy market is expected to grow at the fastest CAGR during the forecast period because cancer cases are increasing, while healthcare facilities improve, and consumers understand the benefits of early cancer detection. The combination of diagnostic technology improvements together with government healthcare modernisation funding leads to major progress in developing countries, including China, India, and Japan. The market growth stems from the expanding use of minimally invasive biopsy methods together with the wider availability of advanced molecular diagnostic systems. The region demonstrates strong potential for global cancer biopsy market growth because it has a large number of patients, along with increasing healthcare expenses and supportive regulations for precision medicine and cancer detection programs.
Key Cancer Biopsy Companies:
The following are the leading companies in the cancer biopsy market. These companies collectively hold the largest market share and dictate industry trends.
Recent Developments
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decision Advisors has segmented the cancer biopsy market based on the below-mentioned segments:
Global Cancer Biopsy Market, By Product
Global Cancer Biopsy Market, By Type
Global Cancer Biopsy Market, By Regional Analysis
Oct 2025 - The Global Tea Subscription Market Size is expected to Grow from USD 485.8 Million in 2024 to USD 1245.3 Million by 2035, at a CAGR of 8.93% during the forecast period 2025-2035.
Oct 2025 - The Global Acute Pancreatitis Market Size Was Estimated at USD 3.07 Billion in 2024 and is Projected to Reach USD 5.77 Billion by 2035, Growing at a CAGR of 5.9% from 2025 to 2035.
Oct 2025 - The Global Hemorrhoids Treatment Market Size Was Estimated at USD 728.03 Million in 2024 and is Projected to Reach USD 1646.23 Million by 2035, Growing at a CAGR of 7.7% from 2025 to 2035.
We have received your message and would like to thank you for writing to us. If your inquiry is urgent, please use the telephone number listed below to talk to one of our staff members. Otherwise, we will reply by email as soon as possible.
+1 303 800 4326 +91 9561448932 emailsales@sphericalinsights.com
